Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence

González‐Costello, José; Cainzos‐Achirica, Miguel; Lupón, Josep; Farré, Núria; Moliner-Borja, Pedro; Enjuanes, Cristina; Antonio, Marta de; Fuentes, Lara; Díez‐López, Carles; Bayés‐Genís, Antoni; Manito, Nicolás; Pujol, Ramón; Comín‐Colet, Josep

doi:10.1016/j.ejim.2020.04.031

Cited by 15 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…iron therapy, independent of baseline Hgb levels. 20,63 The early positive benefits have now been confirmed in the AFFIRM-AHF (A Randomised, Double-Blind Placebo Controlled Trial Comparing the…”

Section: Correcting Anemia or Iron Deficiency In Hfmentioning

confidence: 98%

“…iron therapy have shown significant improvements in quality of life and functional outcomes among patients with HF, they were not designed to evaluate the effects of treatment on event-driven or "hard" outcomes. More recently, evidence from meta-analyses 20,62 and cohort studies 63 however, demonstrate significant reductions in the risk of HF hospitalization with i.v. iron therapy, independent of baseline Hgb levels.…”

Section: Correcting Anemia or Iron Deficiency In Hfmentioning

confidence: 99%

See 1 more Smart Citation

Iron Deficiency in CKD Without Concomitant Anemia

Wish

Anker

Butler

et al. 2021

Kidney International Reports

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Correcting Anemia or Iron Deficiency In Hfmentioning

confidence: 98%

Section: Correcting Anemia or Iron Deficiency In Hfmentioning

confidence: 99%

Iron Deficiency in CKD Without Concomitant Anemia

Wish

Anker

Butler

et al. 2021

Kidney International Reports

View full text Add to dashboard Cite

show abstract

“…Despite optimal gold-standard treatment, a significant number of patients present higher clinical deterioration [ 3 ], suggesting that there are unknown biologic components playing a role in disease progression beyond the typical neurohormonal activation. In this scenario, systemic and myocardial iron homeostasis have emerged as relevant factors that participate in the HF syndrome given that: (1) a significant number of HF patients have systemic ID [ 4 ], (2) patients with ID have a worse clinical course when compared with non-ID patients [ 5 , 6 , 8 , 25 ], and (3) treatment of ID patients with intravenous iron results in significant clinical improvements [ 12 , 13 , 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

Blood Differential Gene Expression in Patients with Chronic Heart Failure and Systemic Iron Deficiency: Pathways Involved in Pathophysiology and Impact on Clinical Outcomes

Díez‐López

Orduña

Grau

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Background: Iron deficiency is a common disorder in patients with heart failure and is related with adverse outcomes and poor quality of life. Previous experimental studies have shown biological connections between iron homeostasis, mitochondrial metabolism, and myocardial function. However, the mechanisms involved in this crosstalk are yet to be unfolded. Methods: The present research attempts to investigate the intrinsic biological mechanisms between heart failure and iron deficiency and to identify potential prognostic biomarkers by determining the gene expression pattern in the blood of heart failure patients, using whole transcriptome and targeted TaqMan® low-density array analyses. Results: We performed a stepwise cross-sectional longitudinal study in a cohort of chronic heart failure patients with and without systemic iron deficiency. First, the full transcriptome was performed in a nested case-control exploratory cohort of 7 paired patients and underscored 1128 differentially expressed transcripts according to iron status (cohort1#). Later, we analyzed the messenger RNA levels of 22 genes selected by their statistical significance and pathophysiological relevance, in a validation cohort of 71 patients (cohort 2#). Patients with systemic iron deficiency presented lower mRNA levels of mitochondrial ferritin, sirtuin-7, small integral membrane protein 20, adrenomedullin and endothelin converting enzyme-1. An intermediate mitochondrial ferritin gene expression and an intermediate or low sirtuin7 and small integral membrane protein 20 mRNA levels were associated with an increased risk of all-cause mortality and heart failure admission ((HR 2.40, 95% CI 1.04–5.50, p-value = 0.039), (HR 5.49, 95% CI 1.78–16.92, p-value = 0.003), (HR 9.51, 95% CI 2.69–33.53, p-value < 0.001), respectively). Conclusions: Patients with chronic heart failure present different patterns of blood gene expression depending on systemic iron status that affect pivotal genes involved in iron regulation, mitochondrial metabolism, endothelial function and cardiovascular physiology, and correlate with adverse clinical outcomes.

show abstract

“…Наразі основними методами лікування анемічного синдрому при захворюваннях, що супроводжуються хронічним запаленням і злоякісних новоутвореннях є призначення препаратів заліза для парентерального (довенного) введення, препаратів еритропоетину, трансфузій середовищ, що містять еритроцити [23,24] ). Исследование содержания свободных фракций гистамина (СГ) и серотонина (СС) в плазме крови осуществляли методом флуориметрического анализа на анализаторе "БИАН-130"-"БИАН-100" по методике Б. В. Михайличенка, С. В. Выдыборца (1999).…”

Section: оптимізація діагностики вторинних метаболічних порушень та лікувальної тактики у пацієнтів із анемією злоякісного новоутворення unclassified

Optimization of Diagnosis of Secondary Metabolic Disorders and Treatment Tactics in Patients with Malignant Neoplasm Anemia in Colorectal Cancer

Andriiaka¹

2021

Ukr. ž. med. bìol. sportu

View full text Add to dashboard Cite

The purpose of the study was to study the content of free fraction of heparin, histamine and serotonin in plasma of peripheral venous blood of patients with malignant neoplasm anemia in colorectal cancer, depending on the severity of anemia. Materials and methods. The material for the study was the blood plasma of 445 patients (228 men and 217 women). Among them, 53 patients (31 women and 22 men) with iron deficiency anemia were examined and included in the first observation group (І) and 392 patients (206 men (52.55 %) and 186 women (47.45 %)) with colorectal cancer whose course of the underlying disease was burdened with malignant neoplasm anemia (ICD-10 code: D63.0) were included in the second observation group (II). Among the patients in the second (II) observation group, there were 222 individuals (119 men and 103 women) with malignant neoplasms of the colon (ICD-10 code: С.18), 29 individuals (16 men and 13 women) with malignant neoplasms of the rectosigmoid junction (ICD-10 code: C.19), 138 individuals (82 men and 56 women) with malignant neoplasms of the rectum (code ICD-10 C.20) and 3 patients (2 men and 1 woman) with malignant neoplasms of the anus (ICD-10 code: C.21). The mean age of the patients was 63.3 ± 1.2 years old. The plasma level of free fraction of heparin of the examined patients was determined using the photocolorimetric method on photoelectric colorimeter 56-M after its preliminary isolation by electrophoretic method according to the appropriate procedure (B. V. Mykhailychenko, S. V. Vydyborets (2000)). The plasma level of free histamine and serotonin of the examined patients was studied using the method of fluorometric analysis on the analyzer “BIAN-130”-“BIAN-100” according to the procedure of B. V. Mykhailychenko, S. V. Vydyborets (1999). Results and discussion. It was found that prior to the initiation of treatment in patients with malignant neoplasm anemia, regardless of the course of colorectal cancer, there was a significant increase in the plasma level of free fraction of heparin, histamine, serotonin (p < 0.001); the ratio of free histamine to free serotonin was also changed in comparison with the values in the control group (p < 0.05), which indicated both an increased release of heparin, histamine and serotonin from the depot, and an impaired inactivation processes of these biologically active substances. Considering all of the above and the quite obvious reasons, namely, the secondary metabolic disorders of serotonin, histamine, heparin which manifested by a significant increase in their plasma level of patients with malignant neoplasm anemia in colorectal cancer, we suggested the need to use a medicinal product in a complex of therapeutic measures which can cause antihypoxic, membrane stabilizing and anti-edema action. Conclusion. Malignant neoplasm anemia in colorectal cancer is accompanied by significant changes in the metabolism of biologically active substances – free fraction of heparin, histamine, serotonin, and the ratio of free histamine to serotonin. It was correctly concluded that in addition to the baseline therapy the administration of arginine glutamate which causes both antihypoxic and membrane-stabilizing action, reliably contributes to the normalization of secondary metabolic disorders of histamine, serotonin and heparin metabolism in malignant neoplasm anemia in patients with colorectal cancer

show abstract

Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence

Cited by 15 publications

References 28 publications

Iron Deficiency in CKD Without Concomitant Anemia

Iron Deficiency in CKD Without Concomitant Anemia

Blood Differential Gene Expression in Patients with Chronic Heart Failure and Systemic Iron Deficiency: Pathways Involved in Pathophysiology and Impact on Clinical Outcomes

Optimization of Diagnosis of Secondary Metabolic Disorders and Treatment Tactics in Patients with Malignant Neoplasm Anemia in Colorectal Cancer

Contact Info

Product

Resources

About